Cost-effectiveness planes and acceptability curves excluding one outlier for (A) the difference in incidence of recurrent sickness absence and (B) time to recurrent sickness absence.

<p>Cost-effectiveness planes and acceptability curves excluding one outlier for (A) the difference in incidence of recurrent sickness absence and (B) time to recurrent sickness absence.</p

Cost-effectiveness planes and acceptability curves for (A) the difference in incidence of recurrent sickness absence and (B) time to recurrent sickness absence.

<p>Cost-effectiveness planes and acceptability curves for (A) the difference in incidence of recurrent sickness absence and (B) time to recurrent sickness absence.</p

Cut-off Values, likelihood ratios, and other test characteristics of I-FABPp (A) and I-FABPu (B) as a predictive test for the presence of NEC from 0–48 h after onset of symptoms (n = 37).

<p>Cut-off Values, likelihood ratios, and other test characteristics of I-FABPp (A) and I-FABPu (B) as a predictive test for the presence of NEC from 0–48 h after onset of symptoms (n = 37).</p

Median I-FABP values (after logarithmic transformation), measured from 0–8 h in plasma (A) and urine (B), of 22 NEC versus 15 no-NEC patients.

<p>Cut-off points to differentiate between groups are represented by dotted lines (after logarithmic transformation: cut-off points at 3.2 and 6.4 ng/mL correspond to cut-off points at 9 and 218 ng/mL, as mentioned in tables <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0121336#pone.0121336.t002" target="_blank">2A and 2B</a>, respectively). A. Based on I-FABPp. B. Based on I-FABPu.</p

Flow chart of patient inclusion.

<p>Flow chart of patient inclusion.</p

Flow chart of patient outcome.

<p>Flow chart of patient outcome.</p

Cut-off values, likelihood ratios, and other test characteristics of I-FABPp (A) and I-FABPu (B) as a predictive test for the development complicated NEC (after NEC has been diagnosed) from 0–48 h after onset of symptoms (n = 22).

<p>Cut-off values, likelihood ratios, and other test characteristics of I-FABPp (A) and I-FABPu (B) as a predictive test for the development complicated NEC (after NEC has been diagnosed) from 0–48 h after onset of symptoms (n = 22).</p

Median I-FABP values (after logarithmic transformation), measured in plasma (A) and urine (B) from 8–16 h, of patients with complicated NEC (n = 11) versus uncomplicated NEC (n = 11).

<p>Cut-off points to differentiate between groups are represented by dotted lines (after logarithmic transformation: cut-off points at 3.9 and 6.5 ng/mL correspond to cut-off points at 19 and 232 ng/mL, as mentioned in tables <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0121336#pone.0121336.t004" target="_blank">4A and 4B</a>, respectively). A. Based on I-FABPp. B. Based on I-FABPu.</p

Characteristics of included patients.

<p>Values are expressed as median (range). NICU = neonatal intensive care unit.</p><p>The remaining 15 patients were diagnosed with ileus caused by sepsis e.c.i. (e causa ignota; n = 3), delayed passage of meconium (n = 2), bloody stool e.c.i. (n = 2), CPAP belly (n = 2), (viral) gastroenteritis (n = 2), spontaneous intestinal perforation (SIP; n = 1), and sigmoid volvulus (n = 1). In two patients no definite diagnosis could be made.</p><p>Characteristics of included patients.</p

Cut-off values, likelihood ratios, and other test characteristics of I-FABPp (A) and I-FABPu (B) as a predictive test for the development of complicated disease (both NEC and otherwise) from 0–48 h after onset of symptoms (n = 37).

<p>Cut-off values, likelihood ratios, and other test characteristics of I-FABPp (A) and I-FABPu (B) as a predictive test for the development of complicated disease (both NEC and otherwise) from 0–48 h after onset of symptoms (n = 37).</p